OS adjusted for crossover from SOC to liso-cel using a 2-stage accelerated failure time model. OS for SOC was estimated based on the outcome if crossover had not occurred (ie, hypothetical scenario to isolate the relative effect of liso-cel vs SOC alone without subsequent anticancer therapy).